MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
Key Details
- 1AI tools are advancing early detection in medical imaging, including lymph node metastases previously missed by standard diagnostics.
- 2Proton therapy is becoming more widespread, with phase III trials (e.g., 440 oropharyngeal cancer patients) showing reduced toxicities versus traditional radiation.
- 3Biomarker research is personalizing prostate cancer care, such as the NRG GU006 trial using genomic tools.
- 4Theranostics and radiopharmaceuticals, like FDA-approved Pluvicto, are expanding from localized to systemic radiation treatments.
- 5MD Anderson researchers are presenting over 65 abstracts at ASTRO covering these innovations.
Why It Matters
AI's integration into medical imaging is quickly improving diagnostic accuracy and treatment personalization in oncology. These advances—especially in clinical trials and real-world applications—are set to directly impact radiology workflows and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI Tool Predicts Financial Toxicity Risk in Cancer Patients
Researchers developed a machine learning model to proactively identify cancer patients at high risk of financial stress from treatment.
•EurekAlert
Researchers Develop All-Optical Synapse for Neuromorphic Imaging Systems
A new artificial synapse, controlled entirely by light, enables in-sensor neuromorphic processing for more efficient and noise-resistant imaging systems.
•EurekAlert
Mayo Clinic Showcases Imaging AI and Early Cancer Detection Advances at ASCO 2026
Mayo Clinic researchers will present over 30 studies at ASCO 2026, highlighting new advances in imaging AI, data science, and early cancer detection.